News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
82,295 Results
Type
Article (6550)
Company Profile (31)
Press Release (75714)
Section
Business (22848)
Career Advice (32)
Deals (3582)
Drug Delivery (14)
Drug Development (20043)
Employer Resources (3)
FDA (2732)
Job Trends (2279)
News (46489)
Policy (4107)
Tag
Academia (377)
Africa (51)
Allergies (12)
Alliances (7894)
Alzheimer's disease (444)
Antibody-drug conjugate (ADC) (67)
Approvals (2728)
Artificial intelligence (15)
Asia (7338)
Australia (937)
Bankruptcy (20)
Best Places to Work (2131)
Biosimilars (29)
Biotechnology (24)
Bladder cancer (12)
Breast cancer (25)
C2C Services and Suppliers (4187)
California (465)
Canada (129)
Cancer (241)
Career advice (29)
CAR-T (14)
Cell therapy (33)
China (55)
Clinical research (14821)
Collaboration (36)
Compensation (11)
Connecticut (16)
COVID-19 (1219)
Data (129)
Delaware (20)
Diagnostics (844)
Earnings (8281)
Europe (15008)
Events (13081)
Executive appointments (20)
FDA (2789)
Florida (38)
Funding (34)
Gene therapy (15)
GLP-1 (121)
Government (823)
Healthcare (2367)
Hotbed/Location (53302)
Illinois (18)
Immunology and inflammation (15)
Indiana (20)
Infectious disease (1231)
Inflammatory bowel disease (37)
IPO (1843)
Job creations (206)
Job search strategy (27)
Layoffs (44)
Legal (340)
Liver cancer (19)
Lung cancer (78)
Lymphoma (15)
Manufacturing (15)
Maryland (52)
Massachusetts (351)
Medical device (883)
Medtech (883)
Mergers & acquisitions (1745)
Metabolic disorders (36)
Minnesota (22)
Multiple sclerosis (15)
Neuroscience (469)
New Jersey (200)
New York (124)
NextGen Class of 2024 (532)
Non-profit (189)
North Carolina (45)
Northern California (226)
Obesity (26)
Opinion (23)
Ovarian cancer (13)
Patents (14)
Pennsylvania (54)
People (5355)
Phase I (5933)
Phase II (6274)
Phase III (4873)
Pipeline (45)
Postmarket research (294)
Preclinical (2271)
Press Release (41)
Radiopharmaceuticals (77)
Rare diseases (18)
Real estate (454)
Regulatory (3231)
Research institute (482)
Series A (11)
South America (67)
Southern California (201)
Startups (481)
Texas (34)
United States (1571)
Vaccines (242)
Washington State (77)
Weight loss (17)
Date
Today (24)
Last 7 days (118)
Last 30 days (523)
Last 365 days (7601)
2024 (5364)
2023 (7626)
2022 (9645)
2021 (10409)
2020 (9068)
2019 (4922)
2018 (3746)
2017 (4279)
2016 (3629)
2015 (4013)
2014 (2828)
2013 (2172)
2012 (2106)
2011 (2214)
2010 (2034)
82,295 Results for "fusion antibodies".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Acquisition of Fusion Pharmaceuticals Completed
Fusion Pharmaceuticals Inc. announced the successful completion of the acquisition of all of the issued and outstanding shares of Fusion by a wholly-owned subsidiary of AstraZeneca AB by way of a statutory plan of arrangement under section 192 of the Canada Business Corporations Act, referred to as the Arrangement.
June 4, 2024
·
6 min read
Pre-clinical result of LP-005, a novel bi-functional complement antibody-fusion protein was unveiled by LongBio at WCN2024
LongBio Pharma (Suzhou) Co., Ltd. (referred to as “LongBio”) proudly announced the release of pre-clinical data of LP-005, a novel bi-functional complement antibody-fusion protein, at the 2024 World Congress of Nephrology (WCN24) held by International Society of Nephrology (ISN).
April 15, 2024
·
3 min read
SAIL Fusion Announces the U.S. Commercial Launch of its BowTie™ Sacroiliac Fusion System
SAIL Fusion, a medical device company focused on advancing the surgical treatment of sacroiliac joint dysfunction through solutions built upon proven AO principles, today announced the U.S. commercial launch of its novel BowTie Sacroiliac Fusion System.
June 12, 2024
·
3 min read
Drug Development
Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting
Innovent Biologics, Inc. presented the Phase 1 clinical data of its first-in-class PD-1/IL-2α bispecific antibody fusion protein in advanced solid tumors at the 2024 ASCO Annual Meeting.
June 1, 2024
·
9 min read
Business
Evommune Secures Exclusive Rights to Develop and Commercialize a Phase 2-ready IL-18 targeted fusion protein from AprilBio
Evommune, Inc. today announced it has entered into a definitive, worldwide license agreement with AprilBio Co., Ltd. (Kosdaq: 397030), a biopharmaceutical company based in South Korea dedicated to developing specialized biologics and antibody drugs, for an IL-18 targeted fusion protein.
June 24, 2024
·
3 min read
Deals
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca
Fusion Pharmaceuticals Inc. announced that at a special meeting of its shareholders, held virtually earlier today, the Shareholders voted in favour of the resolution to approve the previously announced plan of arrangement with a wholly-owned subsidiary of AstraZeneca under the Canada Business Corporations Act pursuant to which AstraZeneca will acquire all of the issued and outstanding shares of Fusion.
May 29, 2024
·
4 min read
Biotech Beach
SAIL Fusion Announces FDA Clearance of its BowTie™ Sacroiliac Fusion System
SAIL Fusion, a medical device company focused on advancing the surgical treatment of sacroiliac joint dysfunction through solutions built upon proven AO principles, today announced that it has received FDA clearance for its novel BowTie Sacroiliac Fusion System.
April 23, 2024
·
3 min read
FDA
Innovent Receives Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α Bispecific Antibody Fusion Protein) as Monotherapy for Advanced Melanoma
September 3, 2024
·
7 min read
Press Releases
Innovent Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress
September 18, 2024
·
9 min read
Biotech Bay
Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold
Biomea Fusion, Inc., announced that the Company has received notice from the U.S. Food and Drug Administration that a full clinical hold has been placed on Biomea’s ongoing Phase I/II clinical trials of the Company’s investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes, respectively.
June 6, 2024
·
6 min read
1 of 8,230
Next